Table 1.
Determinants of Gleason score undergrading between biopsy and prostatectomy
| |
Total |
Cases |
Controls |
Univariate OR1 (95% CI) |
p-value |
Multi-adjusted OR1,2 (95% CI) |
p-value |
|---|---|---|---|---|---|---|---|
| (n = 371) | (n = 95) | (n = 276) | |||||
|
Age at diagnosis years (in continuous ) |
|
|
|
1.04 (1.00-1.08) |
0.049 |
1.04 (1.00-1.09) |
0.038 |
|
Socioeconomic status |
|
|
|
|
|
|
|
| High |
128 |
31 |
97 |
1.00 |
|
|
|
| Middle |
155 |
43 |
112 |
1.20 (0.70-2.05) |
0.502 |
|
|
| Low |
82 |
20 |
62 |
1.01 (0.53-1.93) |
0.977 |
|
|
| Unknown |
6 |
1 |
5 |
0.63 (0.07-5.56) |
0.674 |
|
|
|
Sector of care |
|
|
|
|
|
|
|
| Private |
235 |
48 |
187 |
1.00 |
|
|
|
| Public |
136 |
47 |
89 |
2.06 (1.28-3.31) |
0.003 |
|
|
|
PSA value |
|
|
|
|
|
|
|
| <10 |
242 |
63 |
179 |
1.00 |
|
|
|
| 10-20 |
39 |
14 |
25 |
1.59 (0.78-3.25) |
0.203 |
|
|
| >20 |
12 |
4 |
8 |
1.42 (0.41-4.88) |
0.577 |
|
|
| Unknown |
78 |
14 |
64 |
0.62 (0.33-1.19) |
0.149 |
|
|
|
Clinical stage |
|
|
|
|
|
|
|
| T1-T2 |
272 |
61 |
211 |
1.00 |
|
1.00 |
|
| T3-T4 |
93 |
33 |
60 |
1.90 (1.14-3.17) |
0.014 |
1.81 (1.06-3.10) |
0.030 |
| Tx |
6 |
1 |
5 |
0.69 (0.08-6.03) |
0.739 |
0.58 (0.06-5.37) |
0.628 |
|
Number of biopsy cores |
|
|
|
|
|
|
|
| ≤ 9 |
175 |
56 |
119 |
2.02 (1.24-3.28) |
0.005 |
1.93 (1.16-3.22) |
0.011 |
| 10 + |
185 |
35 |
150 |
1.00 |
|
1.00 |
|
| Unknown |
11 |
4 |
7 |
2.45 (0.68-8.83) |
0.171 |
2.65 (0.70-10.0) |
0.151 |
|
Prostate volume cm3 (in continous) |
|
|
|
0.99 (0.97-1.00) |
0.031 |
|
|
|
Number of procedures performed by the biopsy operator |
|
|
|
|
|
|
|
| 1-29 |
110 |
37 |
73 |
1.75 (1.07-2.87) |
0.026 |
|
|
| 30+ |
254 |
57 |
197 |
1.00 |
|
|
|
| Unknown |
7 |
1 |
6 |
0.58 (0.07-4.88) |
0.613 |
|
|
| Delay between biopsy and prostatectomy days (in continous) | 1.01 (1.00-1.01) | 0.004 | 1.01 (1.00-1.01) | 0.018 |
1) OR: Odds Ratio derived from logistic regression considering as cases patients whose biopsy Gleason score was lower than the prostatectomy Gleason score and as controls everybody else, 2) Simultaneously adjusted for age, pathological stage, number of biopsy cores and delay between the two procedures.